| Title | PharmAbcine, AACR Annual Meeting 2020 |
Category | News Article |
PharmAbcine to Present Preclinical Data on PMC-402, Blood Vessel Stabilization in Tumor Microenvironment at AACR Annual Meeting 2020.
ย
PharmAbcine Inc. (KOSDAQ: 208340) announced today that it will present a poster on PMC-402 at the American Association for Cancer Research (AACR) Annual Meeting 2020 that will be held on Apr. 24th โ Apr. 29th in San Diego, CA. The poster will be presented in the โAngiogenesis and vascular normalization in tumor immunity and treatment responseโ session.
ย
PMC-402 is a next generation therapeutic antibody that regulates the formation of functional blood vessels. During the presentation, PharmAbcine will highlight a unique molecular mechanism of PMC-402 and its anti-tumor activity, supported by preclinical data including changes in capillary formation, improvement of hypoxic condition in TME, and increased numbers of TILs (Tumor Infiltrating Lymphocytes) upon a treatment with PMC-402. PharmAbcine will also present PMC-402โs anti-tumor effect observed in a colon cancer model following a single agent therapy or combination therapy with anti-PD1 antibody. The details of poster presentation are as follows:
ย
Poster Presentation:
- ลธ ย Title: A novel anti-Tie2 antibody stabilized vessel and increased tumor infiltrated lymphocyte
- ลธ ย Session Title: Angiogenesis and Vascular Normalization in Tumor Immunity and Treatment Response
- ลธ ย Session Date and Time: Monday Apr 27, 2020, 9:00 AM- 12:30 PM (PST)
- ลธ ย ย Location: San Diego Convention Center, Exhibit Halls A-F, Poster Section 14
- ลธ ย Poster Board Number: 10
- ลธ ย Permanent Abstract Number: 1483
PharmAbcine has been developing PMC-402 by utilizing years of experience and expertise in developing therapeutic antibodies, including an anti-VEGFR2 antibody, olinvacimab, which is currently in a phase II clinical trial. On the grounds that PMC-402 can constitutively induce normalization of leaky blood vessels formed around tumor mass in a ligand-independent manner, PMC-402 demonstrated its anti-tumor effect in a mouse model of colon cancer, corroborated by the improvement in immune cell infiltration and delivery of anti-cancer agents to a tumor site when administered as a single agent or as a combination therapy regimen. In addition to treating cancer patients, attributed to its notable activity in restoring pathological leaky blood vessels, we expect that PMC-402 will be beneficial to treat AMD or DR patients. PharmAbcine is planning to initiate IND enabling studies this year and submit IND in 2021.
ย
About PharmAbcine Inc.
ย
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody (mAb) therapeutics, especially reputed for leading the development of next-generation multi-specific antibodies. This multi-specific antibody technology can be achieved through our in-house novel technology development, namely DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology and excellent human resources, we provide a number of superlative immunotherapeutics for indications in immuno oncology, immunology and ophthalmology.
ย
PharmAbcineโs HuPhage library and innovative selection system are priceless proprietary assets. Additionally, our well-established 3G expression system ultimately helped concrete our stupendous reputation in the field of biopharma industry by allowing us to achieve the ย reinforcement and reproducibility of high levels of antibody production. On the basis of its highly maintained, advanced technical ย systems, we provide high quality antibody generation services. Moreover, our high standards antibodies have allowed us to be actively involved in co-development with our partners and we are willing to expand co-development opportunities to other potential partners.
ย
Under the collaboration with SAMSUNG MEDICAL CENTER, we have more than 300 patients-derived cancer stem cell libraries and an animal model system for evaluating internal pipeline development.
ย
Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com
ย
Contacts
Yohan Jung
82-42-863-2017
yohan.jung@pharmabcine.com
Category
PharmAbcine to Present Preclinical Data on PMC-402, Blood Vessel Stabilization in Tumor Microenvironment at AACR Annual Meeting 2020.
ย
PharmAbcine Inc. (KOSDAQ: 208340) announced today that it will present a poster on PMC-402 at the American Association for Cancer Research (AACR) Annual Meeting 2020 that will be held on Apr. 24th โ Apr. 29th in San Diego, CA. The poster will be presented in the โAngiogenesis and vascular normalization in tumor immunity and treatment responseโ session.
ย
PMC-402 is a next generation therapeutic antibody that regulates the formation of functional blood vessels. During the presentation, PharmAbcine will highlight a unique molecular mechanism of PMC-402 and its anti-tumor activity, supported by preclinical data including changes in capillary formation, improvement of hypoxic condition in TME, and increased numbers of TILs (Tumor Infiltrating Lymphocytes) upon a treatment with PMC-402. PharmAbcine will also present PMC-402โs anti-tumor effect observed in a colon cancer model following a single agent therapy or combination therapy with anti-PD1 antibody. The details of poster presentation are as follows:
ย
Poster Presentation:
PharmAbcine has been developing PMC-402 by utilizing years of experience and expertise in developing therapeutic antibodies, including an anti-VEGFR2 antibody, olinvacimab, which is currently in a phase II clinical trial. On the grounds that PMC-402 can constitutively induce normalization of leaky blood vessels formed around tumor mass in a ligand-independent manner, PMC-402 demonstrated its anti-tumor effect in a mouse model of colon cancer, corroborated by the improvement in immune cell infiltration and delivery of anti-cancer agents to a tumor site when administered as a single agent or as a combination therapy regimen. In addition to treating cancer patients, attributed to its notable activity in restoring pathological leaky blood vessels, we expect that PMC-402 will be beneficial to treat AMD or DR patients. PharmAbcine is planning to initiate IND enabling studies this year and submit IND in 2021.
ย
About PharmAbcine Inc.
ย
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody (mAb) therapeutics, especially reputed for leading the development of next-generation multi-specific antibodies. This multi-specific antibody technology can be achieved through our in-house novel technology development, namely DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology and excellent human resources, we provide a number of superlative immunotherapeutics for indications in immuno oncology, immunology and ophthalmology.
ย
PharmAbcineโs HuPhage library and innovative selection system are priceless proprietary assets. Additionally, our well-established 3G expression system ultimately helped concrete our stupendous reputation in the field of biopharma industry by allowing us to achieve the ย reinforcement and reproducibility of high levels of antibody production. On the basis of its highly maintained, advanced technical ย systems, we provide high quality antibody generation services. Moreover, our high standards antibodies have allowed us to be actively involved in co-development with our partners and we are willing to expand co-development opportunities to other potential partners.
ย
Under the collaboration with SAMSUNG MEDICAL CENTER, we have more than 300 patients-derived cancer stem cell libraries and an animal model system for evaluating internal pipeline development.
ย
Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com
ย
Contacts
Yohan Jung
82-42-863-2017
yohan.jung@pharmabcine.com